Education
About Us
Working with TipRanks
Follow Us
Biotricity (BTCY)
:BTCY
Top Page
Biotricity
(OTC:BTCY)
Rating:45Neutral
Price Target:―
Positive Factors
Financial performance
Biotricity reported a doubling of free cash flow compared to FY2Q25 on an 11% increase in sales to $3.6M.
Operating efficiency
Biotricity achieved further operating efficiency improvements, with gross margin rising to 76.4%, up from 75.3% in FY2Q25.
Patent acquisition
Patent acquisition enhances Biotricity’s competitive profile in multi-sensor monitoring.
Negative Factors
Investment risks
Investment in Biotricity carries risks common to small-cap companies, such as dilution and competition.
Biotricity (BTCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.47M
Dividend YieldN/A
Average Volume (3M)33.47K
Price to Earnings (P/E)―
Beta (1Y)-0.29
Revenue Growth14.09%
EPS Growth38.18%
CountryUS
Employees55
SectorHealthcare
Sector Strength46
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.05
Shares Outstanding24,751,757
10 Day Avg. Volume44,083
30 Day Avg. Volume33,469
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-1.22
Price to Sales (P/S)0.00
P/FCF Ratio-1.78
Enterprise Value/Market Cap4.56
Enterprise Value/Revenue0.86
Enterprise Value/Gross Profit4.38
Enterprise Value/Ebitda-1.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Biotricity Business Overview & Revenue Model
Company DescriptionBiotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
How the Company Makes MoneyBiotricity makes money through the sale and leasing of its medical devices, primarily the Bioflux device, to healthcare providers, including hospitals and clinics. Revenue is generated from both the initial sale/lease of the device and ongoing service fees for data monitoring and analysis. The company may also engage in partnerships with healthcare organizations to expand its reach and enhance service offerings. Additionally, Biotricity may explore revenue opportunities through research and development collaborations in the medical technology sector.
Biotricity Earnings Call Summary
Earnings Call Date:Feb 20, 2025
(Q2-2025)
| % Change Since: -43.94%|
Next Earnings Date:Jun 27, 2025
Earnings Call Sentiment Positive
The earnings call presents a predominantly positive outlook with significant achievements in EBITDA, revenue growth, strategic partnerships, and market expansion. Despite the continued net loss, the improvements and strategic advancements position Biotricity well for future profitability.Q2-2025 Updates
Positive Updates
Achievement of Positive EBITDA
Biotricity achieved positive EBITDA for the first time in September 2025, marking a significant milestone in their path to profitability.
Revenue Growth
Revenue increased by 13% year-over-year to $3.3 million for the second quarter ended September 30, 2025.
Transition to Flat Fee Model
Biotricity successfully transitioned approximately 75% of their business to a flat fee subscription model, resulting in a 34% year-over-year growth in flat fee revenue.
Gross Profit Improvement
Gross profit for the quarter totaled $2.5 million, up 23% from $2 million in the prior year period, with a gross profit percentage improvement by 1,468 basis points to 75.3%.
Reduction in Operating Expenses
Operating expenses for the second quarter of fiscal 2025 were $2.8 million, a 34% improvement from the previous year, with SG&A expenses decreasing by 35.5%.
Strategic Partnerships and Market Expansion
Biotricity formed strategic alliances with top GPOs and specialist organizations in neurology and pulmonology, expanding their market reach beyond cardiology.
Significant Inventory Procurement
The company placed the largest inventory order in its history, indicating strong confidence in future growth and a clear path to profitability.
International Expansion
Biotricity received approvals from regulatory bodies in other countries, including Canada, allowing them to sell in new jurisdictions.
Negative Updates
Continued Net Loss
Net loss attributable to common stockholders was $1.65 million, although this represents a 57% reduction year-over-year.
Company Guidance
During the Q2 2025 earnings call for Biotricity (BTCY), management provided optimistic guidance marked by impressive financial metrics and strategic advancements. The company achieved a 13% year-over-year increase in revenue, reaching $3.3 million, and improved gross profit by 23% to $2.5 million. Operating expenses decreased by 34%, contributing to a 57% reduction in net loss to $1.65 million. Biotricity reported its first-ever positive EBITDA in September, with EBITDA and adjusted EBITDA improving by 80% and 87% respectively over the previous year. The strategic focus on expanding partnerships, particularly with group purchasing organizations (GPOs), has enabled access to over 90% of U.S. hospitals, facilitating larger sales opportunities. Additionally, the company has made significant strides in reducing selling, general, and administrative expenses by 35.5% and R&D expenses by almost 26%. Looking ahead, Biotricity aims to leverage its robust inventory and strategic alliances to drive sustained growth and profitability in the cardiac care market.Biotricity Financial Statement Overview
Summary
Biotricity demonstrates robust revenue growth but struggles with profitability and financial stability. The high debt levels and negative equity raise concerns about long-term sustainability. While the company is expanding its top line, achieving profitability and strengthening the balance sheet are critical for future resilience.Income Statement
Biotricity shows a positive revenue growth trend with a 37.6% increase from 2023 to 2024 (TTM), indicating strong top-line expansion. However, the company faces substantial profitability challenges with persistently negative EBIT and net profit margins, reflecting ongoing operational inefficiencies and high costs relative to revenues.45
Neutral
Balance Sheet
The company's balance sheet reveals considerable financial strain. With a negative stockholders' equity and a high debt-to-equity ratio, Biotricity is highly leveraged, indicating potential solvency issues. The equity ratio is also negative, further highlighting financial instability and risk.30
Negative
Cash Flow
Biotricity's cash flow statement shows negative free cash flow, though there is a slight improvement in operating cash flow from previous periods. The operating cash flow to net income ratio is negative, suggesting cash generation challenges. However, positive financing cash flows indicate reliance on external funding to support operations.40
Negative
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.27M | 12.06M | 9.64M | 7.65M | 3.38M | 1.42M |
| Gross Profit | 9.86M | 8.36M | 5.44M | 4.57M | 1.27M | 485.77K |
| EBITDA | -5.28M | -8.90M | -15.40M | -18.02M | -13.35M | -10.93M |
| Net Income | -10.67M | -14.09M | -18.66M | -29.13M | -15.49M | -11.07M |
Balance Sheet | ||||||
| Total Assets | 5.99M | 5.94M | 6.51M | 16.68M | 4.44M | 2.00M |
| Cash, Cash Equivalents and Short-Term Investments | 509.60K | 786.06K | 570.46K | 12.07M | 2.20M | 949.85K |
| Total Debt | 25.46M | 23.88M | 19.55M | 15.35M | 4.71M | 2.34M |
| Total Liabilities | 35.78M | 35.92M | 26.36M | 18.82M | 11.27M | 5.00M |
| Stockholders Equity | -29.80M | -29.98M | -19.85M | -2.14M | -6.83M | -3.00M |
Cash Flow | ||||||
| Free Cash Flow | -3.15M | -6.69M | -13.55M | -15.19M | -11.08M | -7.86M |
| Operating Cash Flow | -3.15M | -6.69M | -13.55M | -15.16M | -11.08M | -7.86M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -29.77K | 0.00 | 0.00 |
| Financing Cash Flow | 3.55M | 6.74M | 2.00M | 25.17M | 12.20M | 8.88M |
Biotricity Technical Analysis
Negative
0.37
Price Trends
0.48
Negative
0.47
Negative
0.40
Negative
Market Momentum
-0.03
Positive
34.99
Neutral
13.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTCY, the sentiment is Negative. The current price of 0.37 is below the 20-day moving average (MA) of 0.48, below the 50-day MA of 0.48, and below the 200-day MA of 0.40, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 34.99 is Neutral, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BTCY.
Biotricity Risk Analysis
Biotricity disclosed 49 risk factors in its most recent earnings report. Biotricity reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biotricity Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $9.59M | ― | -151.23% | ― | 3.30% | 31.84% | |
54 Neutral | $10.63M | 0.87 | -499.57% | ― | -33.92% | ― | |
51 Neutral | $7.41B | 0.32 | -61.11% | 2.34% | 16.99% | 1.69% | |
45 Neutral | $9.47M | ― | 42.40% | ― | 14.09% | 38.18% | |
45 Neutral | $9.43M | ― | -45.38% | ― | -48.61% | 32.18% | |
41 Neutral | $7.97M | ― | -72.70% | ― | 5.05% | 26.13% | |
39 Underperform | $9.31M | ― | -56.80% | ― | -91.22% | 11.84% |
* Healthcare Sector Average
Performance Comparison
BTCY
Biotricity
0.37
-0.53
-58.89%
SSKN
Strata Skin Sciences
2.34
-0.73
-23.78%
NURO
Neurometrix
4.58
0.89
24.12%
BMRA
Biomerica
3.20
-0.32
-9.09%
CODX
Co-Diagnostics
0.27
-0.98
-78.40%
PAVM
PAVmed
0.62
-0.20
-24.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.